Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid

被引:11
作者
McDonnel, Samantha J. [1 ]
Liepnieks, Molly L. [1 ]
Murphy, Brian G. [1 ]
机构
[1] Univ Calif Davis, Dept Pathol Microbiol & Immunol, Sch Vet Med, Davis, CA 95616 USA
关键词
FIV; SAHA; Antilatency therapy; HIV; Animal model; HDAC inhibitor; FELINE IMMUNODEFICIENCY VIRUS; CD4+ T-LYMPHOCYTES; HIV-1; INFECTION; PERSISTENCE; CHALLENGE; LATENCY; THERAPY; MODEL; VIVO;
D O I
10.1016/j.antiviral.2014.05.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Feline immunodeficiency virus (FIV) is a naturally-occurring, large animal model of lentiviral-induced immunodeficiency syndrome, and has been used as a model of HIV pathogenesis and therapeutic interventions. HIV reservoirs in the form of latent virus remain the primary roadblock to viral eradication and cure, and FIV has been previously established an animal model of lentiviral latency. The goal of this study was to determine whether administration of the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) to aviremic, chronically FIV-infected cats would induce latent viral reactivation in vivo. A proof-of-concept experiment in a Transwell co-culture system demonstrated the ability of SAHA to reactivate latent virus which was replication competent and able to infect naive cells. Oral SAHA (250 mg/m(2)) was administered with food to four asymptomatic, experimentally Fly-infected cats and one uninfected control cat, and a limited pharmacokinetic and pharmacodynamic analysis was performed. A statistically significant increase in cell-associated FIV RNA was detected in the cat with the greatest serum SAHA exposure, and cell-free viral RNA was detected at one time point in the three cats that achieved the highest levels of SAHA in serum. Interestingly, there was a significant decrease in viral DNA burden at 2 h post drug administration in the same three cats. Though the sample size is small and the drug response was modest, this study provides evidence that in vivo treatment of Fly-infected cats with the HDACi SAHA can induce viral transcriptional reactivation, which may be dependent upon the concentration of SAHA achieved in blood. Importantly, alternative putative antilatency therapy drugs, and multimodal drug combinations, could be studied in this in vivo system. The FIV/cat model provides a unique opportunity to test novel therapeutic interventions aimed at eradicating latent virus in vivo. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 50 条
[31]   Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells [J].
Grebenova, D. ;
Roeselova, P. ;
Pluskalova, M. ;
Halada, P. ;
Roesel, D. ;
Suttnar, J. ;
Brodska, B. ;
Otevrelova, P. ;
Kuzelova, K. .
JOURNAL OF PROTEOMICS, 2012, 77 :406-422
[32]   Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells [J].
Beliakova-Bethell, Nadejda ;
Zhang, Jin X. ;
Singhania, Akul ;
Lee, Vivian ;
Terry, Valeri H. ;
Richman, Douglas D. ;
Spina, Celsa A. ;
Woelk, Christopher H. .
AIDS, 2013, 27 (01) :29-37
[33]   Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization [J].
Zhou, Hongyan ;
Jiang, Sheng ;
Chen, Jianping ;
Su, Shao Bo .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2014, 92 (10) :879-885
[34]   FIV-infected cats respond to short-term rHuG-CSF treatment which results in anti-G-CSF neutralizing antibody production that inactivates drug activity [J].
Phillips, K ;
Arai, M ;
Tanabe, T ;
Raskin, R ;
Volz, M ;
Uhl, EW ;
Yamamoto, JK .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2005, 108 (3-4) :357-371
[35]   Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells [J].
Hou, Mengyi ;
Huang, Zhenglan ;
Chen, Sicheng ;
Wang, Hao ;
Feng, Tianyu ;
Yan, Shujuan ;
Su, Yuxi ;
Zuo, Guowei .
ONCOLOGY LETTERS, 2018, 16 (04) :4663-4670
[36]   Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma [J].
M Duvic ;
C Zhang .
British Journal of Cancer, 2006, 95 :S13-S19
[37]   Suberoylanilide hydroxamic acid represses glioma stem-like cells [J].
Hsu, Che-Chia ;
Chang, Wen-Chang ;
Hsu, Tsung-I ;
Liu, Jr-Jiun ;
Yeh, Shiu-Hwa ;
Wang, Jia-Yi ;
Liou, Jing-Ping ;
Ko, Chiung-Yuan ;
Chang, Kwang-Yu ;
Chuang, Jian-Ying .
JOURNAL OF BIOMEDICAL SCIENCE, 2016, 23 :1-12
[38]   Antitumor Effect of Suberoylanilide Hydroxamic Acid and Topotecan in Renal Cancer Cells [J].
Sato, Akinori ;
Asano, Takako ;
Horiguchi, Akio ;
Ito, Keiichi ;
Sumitomo, Makoto ;
Asano, Tomohiko .
ONCOLOGY RESEARCH, 2011, 19 (05) :217-223
[39]   Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias [J].
Shiozawa, Ken ;
Nakanishi, Takeo ;
Tan, Ming ;
Fang, Hong-Bin ;
Wang, Wen-chyi ;
Edelman, Martin J. ;
Carlton, David ;
Gojo, Ivana ;
Sausville, Edward A. ;
Ross, Douglas D. .
CLINICAL CANCER RESEARCH, 2009, 15 (05) :1698-1707
[40]   Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication [J].
Saha, Bratati ;
Parks, Robin J. .
JOURNAL OF VIROLOGY, 2019, 93 (12)